Total Funding
27
40
Total FundingVenture - Series Unknown raised
Growth Score
-1 pts
Heat Score
8 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
116641
Remedy Pharmaceuticals is a clinical stage pharmaceutical company that develops molecule drugs for acute central nervous system disorders.
- Ann Tunstall: VP, Regulatory And Clinical Operations
- Sven M. Jacobson: CEO, Co-Founder
Biogen
About the Company
Remedy Pharmaceuticals, Inc. develops small molecule drugs that target NCCa-ATP channels in acute central nervous system injuries, including traumatic brain injuries, strokes, and spinal cord injuries. Its RP-1127 is an intravenous version of glyburide, an inhibitor of NCCa-ATP channels that acts through antagonism of the type-1 sulfonylurea
receptor.
The company was founded in 2004 and is based in New York, New York.
